Tags

Type your tag names separated by a space and hit enter

Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial.
Angiology. 2002 Jan-Feb; 53 Suppl 1:S19-22.A

Abstract

The efficacy of pentoxifylline (PXF) in vascular inner ear disease (VIED) was studied comparing PXF and placebo in a 4-week study; 60 patients with unilateral loss of hearing, vertigo, dizziness, tinnitus (analyzed with an analogue scale line), and cochlear flow reduction were included. The aim of the study was to study the effect of PXF (1800 mg/day) in VIED considering clinical outcome and cochlear flow. All patients completed the study. Improvement in cochlear flow (p<0.05) and a decrease in score in both groups were observed. The cochlear flow increase was 287.5% in the PXF group vs 168% in the placebo group (119.5% difference; p<0.02). There was a difference in score decrease (44.1% larger) in the PXF group (p<0.05). PXF was more effective considering flow and symptoms.

Authors+Show Affiliations

Department of Biomedical Sciences, Chieti University and San Valentino Vascular Screening Project, Pe, Italy.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

11865830

Citation

Incandela, L, et al. "Treatment of Vascular Inner Ear Disease With Pentoxifylline: a 4-week, Controlled, Randomized Trial." Angiology, vol. 53 Suppl 1, 2002, pp. S19-22.
Incandela L, Cesarone MR, Belcaro G, et al. Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial. Angiology. 2002;53 Suppl 1:S19-22.
Incandela, L., Cesarone, M. R., Belcaro, G., De Sanctis, M. T., Nicolaides, A. N., Griffin, M., Geroulakos, G., & Ramaswami, G. (2002). Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial. Angiology, 53 Suppl 1, S19-22.
Incandela L, et al. Treatment of Vascular Inner Ear Disease With Pentoxifylline: a 4-week, Controlled, Randomized Trial. Angiology. 2002 Jan-Feb;53 Suppl 1:S19-22. PubMed PMID: 11865830.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of vascular inner ear disease with pentoxifylline: a 4-week, controlled, randomized trial. AU - Incandela,L, AU - Cesarone,M R, AU - Belcaro,G, AU - De Sanctis,M T, AU - Nicolaides,A N, AU - Griffin,M, AU - Geroulakos,G, AU - Ramaswami,G, PY - 2002/2/28/pubmed PY - 2002/3/22/medline PY - 2002/2/28/entrez SP - S19 EP - 22 JF - Angiology JO - Angiology VL - 53 Suppl 1 N2 - The efficacy of pentoxifylline (PXF) in vascular inner ear disease (VIED) was studied comparing PXF and placebo in a 4-week study; 60 patients with unilateral loss of hearing, vertigo, dizziness, tinnitus (analyzed with an analogue scale line), and cochlear flow reduction were included. The aim of the study was to study the effect of PXF (1800 mg/day) in VIED considering clinical outcome and cochlear flow. All patients completed the study. Improvement in cochlear flow (p<0.05) and a decrease in score in both groups were observed. The cochlear flow increase was 287.5% in the PXF group vs 168% in the placebo group (119.5% difference; p<0.02). There was a difference in score decrease (44.1% larger) in the PXF group (p<0.05). PXF was more effective considering flow and symptoms. SN - 0003-3197 UR - https://www.unboundmedicine.com/medline/citation/11865830/Treatment_of_vascular_inner_ear_disease_with_pentoxifylline:_a_4_week_controlled_randomized_trial_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=11865830.ui DB - PRIME DP - Unbound Medicine ER -